Results 51 to 60 of about 3,281 (174)

Efficacy of romiplostim therapy for hematological toxicity in patients with solid tumors

Клинический разбор в общей медицине
Background. Romiplostim is a medicinal product belonging to the group of thrombopoietin receptor agonists that has shown its efficacy and safety in treatment of immune thrombocytopenia. The number of studies focused on the efficacy of this group of drugs
Anna K. Vaskovskaia, Radion V. Tarnovsky
doaj   +1 more source

Radiotherapy‐Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments

MedComm, Volume 7, Issue 10, October 2026.
Radiotherapy for malignancies frequently injures the organs’ systems through oxidative stress, fibrosis, inflammation, and vascular damage. This review systematically maps the epidemiology, pathogenesis, and emerging therapies to propose a mechanism‑network‑targeted framework for integrated, personalized care in radiation oncology.
Xiaowen Ma, Xiaoxuan Zhang, Pujun Zhao, Jiaxin Yang, Zhihao Li, Xiaoyang Han, Yixuan Wang, Zhenzhen Cui, Nian Liu, Min Li   +9 more
wiley   +1 more source

Trilineage hematopoietic recovery with romiplostim in a child with down syndrome and aplastic anemia: A case report and review of literature

Pediatric Hematology Oncology Journal
Background: Severe aplastic anemia (SAA) associated with Down syndrome (DS) is a rare hematological disease with only a few cases reported in the literature.
Dima Abla, Huda Al Habsi, Nasser Al Rahbi, Alyaa Al Mughairy   +3 more
doaj   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, Volume 96, Issue 10, Page 3116-3125, October 2026.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Validation of a biolayer interferometry-based method for the determination of binding (total) antibodies to romiplostim in human serum

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. Romiplostim treatment of patients with idiopathic thrombocytopenic purpura is associated with formation of anti-drug antibodies (ADA), which often leads to the serious adverse events.
A. A. Agafonova, M. V. Zhilyaeva, I. V. Lyagoskin, A. A. Kazarov, A. E. Lisova, R. R. Shukurov   +5 more
doaj   +1 more source

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

American Journal of Hematology, EarlyView.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, Volume 209, Issue 4, Page 1818-1827, October 2026.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

, 2011
Romiplostim, a thrombopoietic agent with demonstrated efficacy against immune thrombocytopenia (ITP) in prospective controlled studies, was recently licensed for adults with chronic ITP. Only France has allowed romiplostim compassionate use since January
Jean-Marc Durand, Gérard Panelatti, Nathalie Dhedin, Laetitia Languille, Gandhi Damaj, Olivier Lambotte, Borhane Slama, François Lefrère, Lionel Galicier, Bruno Royer, Nicolas Schleinitz, Magda Alexis, Gérard Sebahoun, Xavier Delbrel, Jean-François Viallard, Emmanuel Gyan, Marc Michel, Philippe Quittet, Matthieu Mahévas, Philippe Bierling, Françoise Roudot-Thoraval, Jean-François Rossi, Stéphane Cheze, Mehdi Khellaf, Bertrand Godeau   +24 more
core   +1 more source

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

, 2010
We evaluated the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine therapy.
Eunice S. Wang, Ron L. Paquette, Guillermo Garcia-Manero, Kuolung Hu, Hagop M. Kantarjian, Janice L. Gabrilove, Dietmar P. Berger, Peter L. Greenberg, Francis J. Giles, Janet L. Franklin   +9 more
core   +1 more source

Signaling properties of murine MPL and MPL mutants after stimulation with thrombopoietin and romiplostim

, 2020
Thrombopoietin (THPO) and its receptor myeloproliferative leukemia virus oncogene (MPL) regulate hematopoietic stem cell (HSC) quiescence and maintenance, but also megakaryopoiesis.
Modlich, Ute, Heinz, Niels, Kohlscheen, Saskia, Rommel, Marcel, Milde, Christian, Hoerster, Keven, Schenk, Franziska, Roser, Luise   +7 more
core   +1 more source